This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX
A storied Chinese pharma player is aiming for a second shot at joining some pre-revenue biotechs on the Hong Kong Stock Exchange, in an IPO that could fetch anywhere between $500 million and $1 billion.
Hansoh Pharmaceutical Group re-filed its application after first laying out its pitch last September. While it had initially penciled in $1 billion, a source is now telling Reuters that the new range will be $500 million to $800 million — while another indicated $800 million to $1 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.